On the second day of the J.P. Morgan Healthcare Conference, several biopharmaceutical companies outlined both their immediate revenue strategies and longer-term business objectives, focusing on product launches, clinical development, and evolving market approaches through the end of the decade.
AstraZeneca’s Chief Financial Officer Aradhana Sarin reiterated the company’s ambition to reach $80 billion in total revenue by 2030. “Very much within reach,” Sarin said regarding this goal. The company plans to achieve this target through near-term launches such as its hypertension drug baxdrostat, which recently had a new drug application accepted. Other products nearing market introduction include camizestrant for breast cancer and gefurulimab for myasthenia gravis. AstraZeneca is also investing in its oncology pipeline, with eight wholly-owned clinical-stage antibody-drug conjugates (ADCs) under development and two cell therapies that could generate up to $5 billion in peak revenues.
BioNTech is shifting focus from COVID-19 vaccines back to its core oncology business. The company presented its strategy for 2026 at an event on Tuesday, emphasizing acceleration of late-stage programs and a move toward a tumor-driven approach. Analysts from BMO Capital Markets highlighted pumitamig—a PD-1/VEGF bispecific antibody—as central to BioNTech’s current strategy: “Pumitamig is at the heart of the company’s 2026 strategy.” The drug is being studied as both a standalone treatment and in combination with ADCs for various cancers including breast, liver, colorectal, and lung. Upcoming data readouts are expected across multiple indications this year.
BMO analysts noted particular interest in results from a Phase 3 trial in China evaluating pumitamig for first-line triple-negative breast cancer: “Focus remains on the near-term Ph 3 1L [triple-negative breast cancer] China readout.” This study will help determine if pumitamig could serve as “a next-generation IO backbone.” BioNTech has significant commercial hopes riding on pumitamig’s success; it is partnered with Bristol Myers Squibb under an agreement worth up to $7.6 billion in milestone payments.
Competition in the PD-1/VEGF space continues to intensify. AbbVie recently agreed to pay RemeGen $650 million upfront—nearly $5 billion total—for ex-China rights to another PD-1/VEGF bispecific antibody candidate.
Agios Pharmaceuticals announced it aims to unlock more than $10 billion in market opportunity by 2030 by expanding from ultra-rare disease treatments into broader rare disease portfolios. Key assets include AG-181 for phenylketonuria and AG-236 for polycythemia vera; each asset could contribute over $1 billion annually if successful. Agios also sees potential growth through sickle cell disease therapies and anticipates further opportunities by developing tebapivat for lower-risk myelodysplastic syndromes—a potential $4.5 billion market.
Acadia Pharmaceuticals projected sales targets through 2028 that surpass current analyst expectations: approximately $1 billion from antipsychotic Nuplazid and $700 million from Rett syndrome therapy Daybue. BMO Capital Markets described this as evidence of a “disconnect between Street and internal expectations.” Acadia expects growth partly due to launching Daybue STIX—a new oral formulation free of dyes or preservatives—with limited availability planned for early in the year before wider release later on. Expansion of Daybue internationally is also anticipated as a major long-term revenue driver.
Addressing regulatory issues, Acadia CEO Catherine Owen Adams discussed efforts with other small biotechs to advocate against broad application of government drug pricing rules known as Most Favored Nation (MFN). She stated: “I don’t think the administration is out to target small pharma or small biotech particularly. And what we’re trying to do is make sure that they understand that a peanut butter blanket approach to MFN probably would not be the best for U.S. innovation.”
For more details about AstraZeneca at JPM 2026 see https://www.biospace.com/article/jpm26-day-one-glaxosmithkline-unveils-bold-plan-for-r-d-spend-merck-touts-keytruda-growth/.
Further information about AbbVie’s deal with RemeGen can be found at https://www.biospace.com/article/abbvie-bets-nearly-5b-on-remegen-to-vie-for-position-in-hot-bispecific-market/.
To learn more about Acadia Pharma's policy advocacy efforts visit https://www.biospace.com/article/acadia-ceo-bands-with-peers-to-lobby-against-mfn-drug-pricing-for-small-biotech/.
